The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Os anyone here looking to attend the forthcoming Proactive Investors F2F Forum at The Chesterfield Mayfair Hotel on 8th September?
Looks timely with regards to forthcoming quarterly results update and Serenity progress....
DYOR
Those of you fretting over the late quarterly reporting need to chill a bit. It ain't going to drive up the SP when it comes imo due to current narket conditions. Getting yourselves all worked up about something you have no control over, is not healthy imo.
DYOR
I guess it depends what you mean by meaningful profit - this is subjective of course. But I assume you mean into the tens of millions rather than single digit as will likely be the case here for the next 1-3 years?
Also, I have yet to hear YK buy any stock yet unless I have overlooked this and we could also do with some IIs to bolster the book a bit as this to me appears thin on the ground.
DYOR
(Alliance News) - Analysts were upbeat after Open Orphan unveiled a "substantial" new GBP10.4 million contract which is expected to underpin revenue in 2023.
Shares in the London-based pharmaceutical services firm were up 5.7% to 11.89 pence each in London on Monday morning.
On Monday, Open Orphan said its subsidiary hVIVO has signed a GBP10.4 million contract with an "existing top five global pharmaceutical client". This is the third human challenge contract signed with the client, it added.
Mark Brewer, finnCap analyst, said "This is the fourth human influenza challenge (seventh challenge study) and third challenge virus manufacture that Open Orphan has signed in 2022, illustrating big pharma's recognition of the benefit of conducting challenge studies prior to larger, more expensive field trials."
Under the contract, clinical research company hVIVO is contracted to manufacture a new batch of H1N1 influenza challenge virus, leveraging off an existing in-house generated challenge model, and to conduct a human challenge trial to test the client's antiviral product.
Manufacturing activities will begin immediately and are expected to be complete by the second quarter of 2023.
Once completed, hVIVO will conduct a phase 2a double-blinded placebo-controlled human challenge study which is expected to be complete by the fourth quarter of 2023.
The majority of revenue from the contract is expected to be recognised during 2023, Open Orphan added.
Liberum analyst Edward Thomason estimated that around 70% of the revenue will be recognised during 2023.
Brewer said: "This contract underpins the growing order book of revenues 2023.
"We make no changes to our financial year 2022 forecasts or 44p target price, but clearly the contract win is another positive development for Open Orphan's business model, with challenge model revenues now expected to exceed financial year 2022 levels," Brewer added.
Meanwhile, Thomason said: "Momentum continues to build, and prelims in September (projected) will give good granularity of the progress made to date with management guiding to GBP50 million of revenue in 2022."
By Sophie Rose; sophierose@alliancenews.com
Was is a shock tho? I'm not sure it was. Writing has been on the wall since streaming platforms multiplied.
DYOR
That's helpful, thanks.
It's more than a dilution - its bankruptcy. They'll be nothing left for anyone.
DYOR
Definitely a capital raise imo - and sooner than later I think. My view is the SP is going to head downwards as the market digests the news.
DYOR
Another interview with EOG ahead of Serenity spud - this time, its with Proactive. Link below (hopefully):
https://www.youtube.com/watch?v=Yf4VPxxz0Z4
An interesting and positive update from EOG/i3E re Serenity in today's London South East CEO update with Donald & Simon. Not sure if I can copy the link here, but its easy to find nonetheless:
https://www.youtube.com/watch?v=-1MnyRcP7Rg
DYOR
LC loves using the word 'tremendous' - its his favourite, to describe anything remotely positive about the opportunities that may be ahead in the future. I think 2023 will be a pivotal year - not sure if tremendous would be my word, maybe good or better?
DYOR
I believe spread is one of the concerns imo. Pivoting back to wellness from Covid is a concern for me and it remains to be seen what the impact of selling these new products via Amazon will have on the bottom line. I hope marketing is stepped up and that client engagement is positive and meaningful to ensure value is rewarded for the effort that has clearly been put in so far in developing and launching these new products.
DYOR
Not really sure what the problem is with this deal - has to be agreed by shareholders, so lets see what the outcome is. Even if the next deal is Roast PR, again, the shareholders decide and again, the voting outcome settles it. If you don't like it, sell up (if you are invested) or vote against the proposal.
DYOR
I agree, each recession is a little different driven by various factors. What is clear is that oil has always retreated from my analysis. Demand goes down as people cut back usage during recessions - this one is no different e.g. driving / travelling less as one example.
I think we cannot kid ourselves, a recession is definite in the UK and elsewhere more broadly in my view and a long one at that for the UK. But it won't impact everyone.
DYOR
That's all very well, but when there is a settlement on Russia / Ukraine crisis at the same time as we enter a year-long recession (soft or otherwise), the oil price will drop off a cliff. Just look at what has happened with the oil price during the last recessions. I can see this retreating to c.US$50 per barrel / equivalent. So, I can see the SP retreating here too and potentially quite substantially to the teens. I cannot see Serenity success (if this were to happen) making that much difference in the SP once it has sunk, it may bring it back a little, but not to the levels I think we would all like to see i.e. 30/40s. I am going to be cautious and top-slice (as you should) when we spud but before the recession figs start getting priced in. All of this is just in my opinion.
DYOR
Pre-tax loss, wholesale revenue decline significantly lower than previous guidance. I cannot see this surviving and will likely be bought out imo.
DYOR